Stem Cell Therapy for Back Pain: What the Evidence Actually Shows

Stem cell therapy for back pain is an investigational injection of regenerative cells, most often mesenchymal stem cells from bone marrow, fat or donor tissue, into a degenerated lumbar disc or facet joint, and no stem cell product is FDA approved for back pain in the United States. Small randomized trials, such as a 24-patient trial by Noriega and colleagues in Transplantation (2017), report pain and disability improvements in a subset of patients, but larger placebo-controlled trials have not yet made it standard care.

Back pain is the leading cause of disability worldwide, affecting roughly 540 million people at any given time, according to the Lancet Low Back Pain Series led by Hartvigsen and colleagues (2018). The Global Burden of Disease Study 2021 estimated 619 million people were living with low back pain in 2020. For most people, the standard playbook is physical therapy, anti-inflammatories, and, eventually, surgery. But surgery for degenerative disc disease carries real risks and modest long-term outcomes. That gap in the treatment ladder is exactly where stem cell therapy is being explored.

Stem cell therapy is not a fix that works for everyone, and it is not yet mainstream medicine. The science is moving fast enough, though, that anyone dealing with chronic disc-related back pain should understand what the evidence actually shows and where it stops.

What Is Stem Cell Therapy for Back Pain?

Stem cell therapy for back pain refers to injecting biologically active cells, most commonly mesenchymal stem cells (MSCs), into damaged spinal structures, primarily intervertebral discs and facet joints. The goal is to slow degeneration and calm the pain generator rather than just mask pain.

MSCs are found in bone marrow, adipose (fat) tissue, and umbilical cord tissue. They do not simply become new disc cells. Instead, they release anti-inflammatory cytokines and growth factors that may reduce inflammation, stimulate the disc’s own cells (nucleus pulposus cells) to regenerate, and slow the breakdown of the extracellular matrix that gives discs their structure.

The same treatment appears under several names: intradiscal cell therapy, stem cell injections for back pain, regenerative medicine for back pain, orthobiologics, and mesenchymal stromal cell therapy (many researchers prefer "stromal" because these cells are not true stem cells in the strict sense). Injections are usually performed by interventional pain physicians, physical medicine and rehabilitation physicians (physiatrists) or orthopedic spine surgeons, under fluoroscopy or CT guidance. The stem cell therapy treatment guide covers the wider uses of these cells, and the guide to disc degeneration treatment places them alongside conventional options.

The Problem Stem Cells Are Trying to Solve

Intervertebral discs are largely avascular, meaning they have very limited blood supply. This makes self-repair extremely slow and unreliable. Once the nucleus pulposus (the gel-like inner core) loses water content and the annulus fibrosus (the outer ring) starts to crack, the disc progressively loses height and shock-absorbing capacity.

This degeneration leads to nerve compression, facet joint overload, and the familiar constellation of symptoms: axial lower back pain, stiffness in the morning, pain that worsens with sitting, and in some cases, radiating leg pain from nerve root irritation.

Which back conditions is it used for?

Clinics and trials use cell injections mainly for discogenic low back pain from degenerative disc disease, with facet joint arthropathy as a second target. Some clinics also offer them for sacroiliac joint pain, annular tears and nerve root pain from a bulging disc, where the evidence is thinner still. Pain that comes from the sacroiliac joint or from a compressed nerve root, as in sciatica, needs its own diagnosis first, because an injection into the wrong structure will not help.

Is Stem Cell Therapy for Back Pain FDA Approved?

No. The FDA has not approved any stem cell or other cell-based product to treat back pain, degenerative disc disease or facet joint pain. The FDA's list of approved cellular and gene therapy products includes cord blood products for blood and immune disorders and one mesenchymal stromal cell product approved in December 2024 for steroid-refractory acute graft-versus-host disease in children. Nothing on that list is approved for spine use.

Cells and tissues used in clinics are regulated under 21 CFR Part 1271. A narrow group of products that are only minimally manipulated and used for the same basic function they had in the donor can be used without FDA approval. Cells that are culture-expanded, or used for a different function such as rebuilding a disc, are treated as biologic drugs that need an approved license or an investigational new drug (IND) application. The FDA's consumer information on regenerative medicine therapies warns that unapproved products have caused serious harm, including infections, and that a clinic using a patient's own cells does not make a product legal or safe by default.

Same-day bone marrow concentrate procedures often sit in the minimally manipulated group, which is one reason they are widely offered. Fat-derived stromal vascular fraction (SVF), which uses enzymes to break down tissue, is a different matter: in 2021 a federal appeals court upheld the FDA's position that SVF is a drug requiring approval. Legitimate trials are listed on ClinicalTrials.gov, and the companion post on which stem cell treatments are FDA approved explains the approval categories in more detail.

Types of Cells Used

Not all “stem cell” injections are the same. The source of the cells matters enormously for both safety and efficacy.

Autologous Bone Marrow Concentrate (BMAC)

BMAC uses the patient’s own bone marrow, typically harvested from the iliac crest of the hip under local anesthesia. The marrow is then centrifuged to concentrate the stem and progenitor cells before injection. Because it uses your own cells, immune rejection is not a concern. The drawback is that MSC yield declines with age, meaning older patients may get fewer active cells per injection.

Adipose-Derived Stem Cells (ADSCs)

Fat tissue contains a higher concentration of MSCs than bone marrow. ADSCs are harvested via a mini-liposuction procedure, processed, and injected. Several clinics prefer this source because of the higher cell yield. A single-arm study by Comella and colleagues in the Journal of Translational Medicine (2017) injected stromal vascular fraction plus PRP into the discs of 15 patients and reported improved pain ratings and flexion at six months, with no serious adverse events over 12 months. With no control group, the study shows feasibility rather than efficacy.

Allogeneic (Donor) Cells

Some clinics and clinical trials use MSCs derived from umbilical cord tissue (Wharton’s jelly) or placental tissue donated after birth. These “off-the-shelf” products are more standardized and can be used immediately without a harvest procedure. The immunosuppressive properties of MSCs generally prevent rejection, but allogeneic products carry more regulatory complexity and are not FDA-approved for this indication in the United States. Allogeneic mesenchymal precursor cells (MPCs), a more selected donor cell type, are the most studied donor option for discs and remain investigational.

Platelet-Rich Plasma (PRP)

PRP is not technically stem cell therapy, but it is often grouped with it and frequently used as a comparison or adjunct. PRP is derived from centrifuged whole blood and concentrates growth factors including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-b), and vascular endothelial growth factor (VEGF). Evidence for PRP in disc degeneration is modest but supports its role in facet joint injections. The PRP treatment guide covers preparation methods, and the comparison of PRP versus stem cell therapy sets the two side by side.

Intradiscal Injections: What the Evidence Shows

The most studied application is direct injection into the degenerated disc, guided by fluoroscopy or CT imaging. The clinical trial data so far shows signals of benefit in small studies and mixed results when cells are compared against a sham.

A randomized controlled trial by Noriega and colleagues, published in Transplantation in 2017 (n=24), assigned patients with lumbar degenerative disc disease to allogeneic bone marrow MSCs injected into the disc or a sham injection of anesthetic into the back muscles. Over 12 months, the MSC group showed faster and greater improvement in pain and disability scores, and disc degeneration on MRI, graded by the Pfirrmann scale, improved in treated patients while it worsened in controls. The authors noted that the benefit seemed concentrated in a group of responders making up about 40% of the cohort.

An open-label pilot study by Pettine and colleagues in Stem Cells (2015) injected autologous bone marrow concentrate into the discs of 26 patients. Pain and Oswestry Disability Index scores fell substantially through 12 months, 8 of 20 imaged patients improved by one modified Pfirrmann grade, and patients who received higher concentrations of MSCs did better. Without a control group, the placebo response cannot be separated from the treatment effect.

The broadest current summary is a 2026 systematic review of 13 randomized controlled trials by Zhang, Aurangzeb and Sirisena in the European Spine Journal. It found that autologous BMAC and MSC preparations did not outperform sham controls on primary pain and function outcomes in two 2025 trials, while allogeneic mesenchymal precursor cells showed durable improvements in pain and disability versus saline in a large multicenter trial. The authors concluded that intradiscal PRP, BMAC and autologous MSCs show limited efficacy and that allogeneic MPCs are the most promising cell therapy but remain investigational.

The largest completed trial in this field is a Phase 3 placebo-controlled study of allogeneic mesenchymal precursor cells, with or without hyaluronic acid, in 404 people with chronic low back pain (NCT02412735). Its primary endpoint required at least a 50% drop in pain, a 15-point improvement in the Oswestry Disability Index, and no further intervention at the treated disc at both 12 and 24 months. No cell product for disc pain has been approved on the strength of these trials so far.

Facet Joint Injections

Facet joint degeneration contributes to back pain in roughly 15-45% of chronic low back pain patients. PRP injections into facet joints have more clinical evidence than MSC injections at this specific site. A randomized trial by Wu and colleagues in Pain Practice (2017) (n=46) compared intra-articular PRP with local anesthetic plus corticosteroid for lumbar facet joint syndrome: the steroid group did better early, but its success rate fell sharply by six months, while PRP gave more lasting relief. The 2026 European Spine Journal review reached the same conclusion, with lumbar facet PRP outperforming steroids at six months. More on this pain source is in the post on facet joint syndrome.

Cell Type	Source	Evidence Level	Key Advantage	Key Limitation
Autologous BMAC	Patient’s hip bone marrow	Emerging	No rejection risk	Lower cell yield with age
Adipose MSCs	Patient’s fat tissue	Emerging	Higher cell concentration	Requires mini-liposuction
Allogeneic MSCs	Umbilical cord / donor	Emerging	Standardized, off-the-shelf	Not FDA-approved; regulatory complexity
PRP	Patient’s blood	Moderate (facet joints)	Well-tolerated, low cost	Not true stem cells; variable preparation

Does stem cell therapy work for lower back pain?

Stem cell therapy for lower back pain helps some patients in small trials, but it has not consistently beaten sham injections in controlled studies. The strongest randomized data so far favors allogeneic donor precursor cells, which are not available outside trials, while the autologous bone marrow and fat preparations most clinics sell have the weakest controlled evidence. Expect a meaningful chance of no response, and treat any clinic quote of a high success rate with care.

How Stem Cell Therapy Compares With Other Back Pain Treatments

Stem cell injections sit between conservative care and surgery on the treatment ladder for chronic low back pain. Clinical practice guidelines, including the American College of Physicians guideline (2017), recommend starting with nondrug care such as exercise, physical therapy, spinal manipulation and cognitive behavioral approaches. The table below compares stem cell therapy with the options patients most often weigh against it. The low back pain treatment guide covers each option in more depth.

Treatment	What it targets	Evidence status for chronic low back pain	Usually covered by insurance?
Physical therapy and exercise	Strength, mobility and pain processing	First-line in guidelines	Usually yes
Epidural steroid injection	Inflamed nerve roots	Short-term relief for radicular leg pain	Usually yes
Radiofrequency ablation	Medial branch nerves of the facet joints	Established for confirmed facet pain	Often, with prior authorization
PRP injection	Facet joints, sacroiliac joints, discs	Moderate for facet joints, mixed for discs	Rarely
Prolotherapy	Ligaments and sacroiliac joint	Limited and mixed	Rarely
Stem cell therapy (BMAC, MSCs)	Degenerated discs and facet joints	Emerging and investigational	No
Spinal fusion or disc replacement	Unstable or severely degenerated segments	Established for selected structural problems	Usually yes, when criteria are met

For ligament and sacroiliac pain, some patients look at prolotherapy injections, and for disc-related leg pain others try nonsurgical spinal decompression therapy. The wider overview of regenerative medicine for back pain compares PRP, prolotherapy and cell-based options in one place.

Who Is a Candidate?

Stem cell therapy for back pain is not appropriate for everyone. The usual candidates share a specific clinical profile, confirmed by an MRI and an examination by a spine specialist.

Good Candidates

• Patients with confirmed degenerative disc disease on MRI (Pfirrmann Grade II-IV, meaning moderate but not end-stage degeneration)
• Axial low back pain with or without mild radiculopathy, where the disc is the primary pain generator
• Non-smokers or former smokers (smoking significantly impairs disc cell viability and reduces treatment response)
• Patients who have completed at least 6 weeks of physical therapy, tried anti-inflammatory medications, and have not responded adequately
• Patients trying to avoid or delay spinal fusion surgery

Poor Candidates

• Complete disc collapse (Pfirrmann Grade V) where there is essentially no viable disc tissue remaining
• Spinal instability requiring fusion (spondylolisthesis with significant slip)
• Severe spinal stenosis requiring decompression surgery
• Active infection or malignancy
• Patients on immunosuppressive medications (may reduce cell activity)
• Patients with significant psychological contributors to pain (these predict poor outcomes regardless of treatment)

The Pfirrmann scale grades disc degeneration on MRI from Grade I (healthy disc) to Grade V (collapsed disc). Trials have generally enrolled patients in the middle grades, because a disc with some living tissue is more likely to respond. People whose pain is spread across the body, as in widespread chronic pain or fibromyalgia, are less likely to benefit from treating a single disc.

What the Procedure Looks Like

For autologous BMAC or ADSC procedures, the process typically spans two visits. The first visit involves the harvest: bone marrow aspiration from the iliac crest or fat harvest via small incision, usually under local anesthesia with light sedation. The sample is then processed in an on-site centrifuge over 20 to 30 minutes.

The injection itself is performed under fluoroscopic guidance with the patient prone. A needle is advanced into the disc space, and the cell concentrate is injected directly into the nucleus pulposus. The procedure takes 30 to 60 minutes total. Most patients go home the same day.

Post-procedure, activity restriction for 1 to 2 weeks is typical. Patients are usually advised to avoid heavy loading of the spine. Anti-inflammatory medications like NSAIDs are often stopped before and after treatment because inflammation is part of the healing signal that stem cells need to work.

Steps in a typical stem cell injection for back pain

1. Evaluation: a spine specialist reviews a recent MRI, examines you and may order diagnostic blocks to confirm which disc or joint is the pain generator.
2. Harvest: for autologous treatment, bone marrow is drawn from the back of the hip or fat is collected by mini-liposuction under local anesthesia.
3. Processing: the sample is spun in a centrifuge to concentrate cells, while donor products arrive already prepared.
4. Injection: the physician guides a needle into the disc or facet joint under fluoroscopy or CT and delivers the cells.
5. Recovery and follow-up: a period of reduced loading is followed by gradual return to activity, physical therapy and repeat pain, function and MRI assessments.

Limitations and Honest Caveats

The honest limitation of stem cell therapy for back pain is that we do not yet have large, multicenter, placebo-controlled trials with long-term follow-up that have led to an approved product. Most studies published so far have been relatively small and short. The placebo effect for any injection-based back pain treatment is substantial, sometimes accounting for 30-40% of reported improvement.

There is also the question of cell survival in the disc environment. The disc is a nutrient-poor, low-oxygen, acidic environment. Injected cells face a hostile microenvironment, and it is not clear how many survive and remain active long-term.

Regulatory status is another issue. In the United States, the FDA classifies most stem cell preparations for disc injection as investigational. Clinics offering these treatments outside of IRB-approved clinical trials exist in a regulatory gray zone. The quality and consistency of cell preparations varies widely between clinics.

What are the risks of stem cell injections in the back?

The main procedural risks are infection of the disc (discitis), bleeding or pain at the harvest site, a flare of back pain after injection, and nerve irritation from the needle. Puncturing a disc is not risk free in itself: a 10-year matched cohort study by Carragee and colleagues in Spine (2009) found faster degeneration in discs that had been punctured for discography. Products from unregulated sources add the risk of contamination or of receiving cells different from what was described.

Cost and What to Expect

Stem cell therapy for back pain in the United States typically costs $5,000 to $15,000 per treatment session. The range reflects differences in cell source (autologous vs. allogeneic), the number of disc levels treated, imaging guidance fees, and facility charges.

Insurance does not cover this treatment. It is considered experimental. Some patients travel to countries like Germany, Mexico, or Thailand where costs are lower ($2,000 to $8,000) but regulatory oversight may also be lower. The post on stem cell therapy in Mexico covers what to check before traveling for treatment.

Repeat injections may be needed. Some protocols call for two injections spaced 6 to 12 months apart. Most reputable programs include at minimum a baseline MRI, a follow-up MRI at 12 months, and standardized pain and function assessments so outcomes can be tracked. Ask for an itemized written quote that separates the harvest, processing, imaging, facility and follow-up charges, and see the wider stem cell therapy cost breakdown for how pricing varies by condition.

Questions to Ask Any Clinic

• What cell source and preparation method do you use, and what is the cell count and viability testing protocol?
• Are you collecting outcomes data? If so, what database are you submitting to?
• What imaging guidance do you use for injection (fluoroscopy vs. CT vs. ultrasound)?
• What is your response rate based on your own patient data?
• What happens if the treatment does not work? Does it preclude future surgical options?
• Is this product FDA approved for my condition, and if not, is it given under an IND or a trial registered on ClinicalTrials.gov?
• Who performs the injection, and what is their board certification in pain medicine, physiatry or spine surgery?

For most patients, stem cell therapy for back pain sits in the category of “reasonable to consider after conservative care has failed, provided you find a rigorous program, understand the evidence limitations, and can afford it out of pocket.” It offers no certainty of relief, but the early data is sufficiently promising that dismissing it entirely would also be premature.

For broader context on regenerative treatments for musculoskeletal conditions, see our guide to regenerative medicine approaches and our overview of available treatments.

To compare providers, the Regenerated.com directory of stem cell therapy clinics lists practices by state and city, and it is free for patients to use. Listing order is not paid ranking. Featured slots are labeled and capped, and Verified means a clinic has completed credential checks, not that it paid for placement. Inclusion in the directory is not an endorsement, so bring the questions above to any clinic you contact. The guide to Featured, Verified and organic listings explains each label.

Frequently asked questions

Is stem cell therapy for back pain FDA approved?

No stem cell product is FDA approved to treat back pain, degenerative disc disease or facet joint pain in the United States. The only approved mesenchymal stromal cell product is licensed for a blood and immune complication in children, not for the spine. Clinics may offer minimally manipulated same-day preparations such as bone marrow concentrate without approval, while culture-expanded or donor cells for disc repair should only be given inside a registered clinical trial or under an FDA investigational new drug application.

How much does stem cell therapy for back pain cost?

Stem cell therapy for back pain in the United States typically costs $5,000 to $15,000 per treatment session, and insurance does not cover it because it is considered experimental. The price depends on the cell source, how many disc levels are treated, imaging guidance and facility fees. Some protocols add a second injection 6 to 12 months later, so ask for an itemized written quote that includes harvest, processing, imaging and follow-up MRI.

How long do stem cell injections for back pain take to work?

Stem cell injections for back pain are not an instant fix, and trials track results at 3, 6 and 12 months rather than days. In the 2017 Noriega trial, patients who responded improved early and kept improving through one year, and in the 2015 Pettine pilot, pain scores fell through 12 months. Many patients notice a short flare of soreness after the injection before any improvement, and some never respond at all.

Is stem cell therapy better than PRP for back pain?

Neither stem cell therapy nor PRP has been shown to be clearly better for every type of back pain. PRP has the stronger evidence for lumbar facet joint pain, where randomized trials show it outlasts steroid injections at six months. For disc degeneration, a 2026 systematic review in the European Spine Journal found limited benefit from intradiscal PRP, bone marrow concentrate and autologous MSCs, with donor precursor cells the most promising option, still investigational.

Can stem cell therapy help me avoid back surgery?

Stem cell therapy may help some people with moderate disc degeneration delay spinal fusion, but no trial has yet shown that it reliably prevents surgery. The best results in studies come from patients with Pfirrmann Grade II to IV discs, no spinal instability and pain clearly traced to one or two discs. Ask the treating physician whether the injection would limit future surgical options, and get a second opinion from a spine surgeon first.

Does insurance cover stem cell injections for the back?

Insurance generally does not cover stem cell injections for the back, because Medicare and private insurers classify them as experimental or investigational for spine conditions. Patients usually pay the full cost out of pocket, often $5,000 to $15,000 per session. Health savings account rules vary, so check with your plan administrator. Patients enrolled in a registered clinical trial may receive the study treatment at no cost, which is one reason to search ClinicalTrials.gov first.

---

Related Reading

• PRP Therapy: How Platelet-Rich Plasma Works and What It Treats
• Stem Cell Therapy: Types, Evidence, Cost, Risks, and What You Need to Know